Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 1,98 € (-80,68%). La mediana è 1,82 € (-82,24%).
| Acquista |
3 |
| Mantieni |
13 |
| Vendi |
2 |
Discussioni nella community
- Ticker Symbol neben ISIN und WKN
Hallo zusammen, wenn möglich würde ich gerne parallel zur ISIN und WKN das zugehörige Tickersymbol in der Übersicht zum Wertpapier sehen: Beispiele Aktie Amarin Co. ADR ISIN US0231112063 WKN A0NBNG…
OM Olaf Müller IV in Portfolio Tracking
3 2
Notizie Vai al feed delle notizie
Amarin reports 42% revenue decline after missing prior-year license payment
Amarin reported a 42% decline in net revenues for Q2, mainly due to the absence of a $25m license prepayment from Recordati in the prior-year period. Operating expenses fell 59% to $27m after completing a $70m cost‑reduction initiative. US sales of VASCEPA decreased slightly because of generic competition and net price pressure, partly offset by demand; the company recorded its third consecutive quarter of positive cash flow and expects international growth, stable US sales volumes, positive cash flow and a 10% increase in liquid funds by the end of 2026. » Altro su de.investing.com
Amarin emphasizes cost advantage of VASCEPA after approval of new injectable therapies
Amarin clarifies that VASCEPA remains a treatment option for severe hypertriglyceridemia and reduced triglycerides by a median of 33% versus placebo. About 50% of patients reached levels below 500 mg/dL after 12 weeks. The company highlights that the annual wholesale prices of the new injectable APOC3 therapies are around $40,000, while VASCEPA costs about $4,200 per patient. Amarin also points to over 30 million prescriptions and the cardiovascular approval in combination with statins. » Altro su de.investing.com
Amarin shareholders block share issuances and restrict equity compensation
Amarin shareholders rejected several key proposals, including the renewal of the authorization to issue new shares, an increase in the reserve under the 2020 Stock Incentive Plan, and the issuance of shares without UK pre-emption rights. While the re-election of several board members and the advisory approval of executive pay were passed, they received lower support levels. The board warns this will severely limit the grant of equity-based incentives, make future variable pay primarily cash‑based, and incur additional costs for paper shareholder communications. Shareholders approved the appointment of Ernst & Young as auditor for fiscal year 2026. » Altro su de.investing.com
Amarin increases sales and reduces operating loss through restructuring
Amarin reported a 7.4% increase in total net revenue for Q1 2026 to $45.1 million and, thanks to restructuring measures, cut operating expenses by 31%. The operating loss fell 32.7% to $11.3 million. The company generated positive cash flow for the second consecutive quarter ($6.4 million) and held $308 million in cash at quarter-end. Vascepa prescriptions in the US rose 17%, and the partnership with Recordati contributed to strong revenue growth in Europe. Amarin expects positive full-year cash flow for 2026 and forecasts Q2 EPS of $0.54, but notes risks from generic competition and regulatory hurdles. » Altro su de.investing.com
Amarin to release quarterly results on Feb. 25, 2026
Amarin will release results for the quarter ended Dec. 31, 2025 on Feb. 25, 2026. Three analysts see an average EPS of $0.034 per share, after a loss of -$2.380 in the year-ago quarter. The consensus expects quarterly revenue of $54.6 million (‑11.6% vs. $61.7 million a year earlier). For the fiscal year, three analysts on average forecast a loss of -$0.661 per share and revenue of $222.5 million compared with $228.7 million the prior year. » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 34,92 Mln | 17,50% |
| Utile lordo | 14,29 Mln | 24,51% |
| Utile netto | 216,3K | 103,28% |
| EBITDA | 842,24K | 219,08% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 213,04 Mln € |
Numero di azioni | 20,68 Mln |
Massimo/minimo a 52 settimane | 15,76 € - 10,25 € |
| Dividendi | No |
Beta | 0,79 |
Rapporto P/E | -10,80 |
Rapporto PEG | -0,07 |
Rapporto P/B | 0,53 |
Rapporto P/S | 1,33 |
Profilo aziendale
Amarin Corporation plc, una società farmaceutica, si occupa dello sviluppo e della commercializzazione di terapie per il trattamento delle malattie cardiovascolari negli Stati Uniti, in Germania, Canada, Libano e Emirati Arabi Uniti. Il suo prodotto principale è VASCEPA, un prodotto a base di acidi grassi omega-3 disponibile solo su prescrizione medica, utilizzato come coadiuvante della dieta per ridurre i livelli di trigliceridi in pazienti adulti affetti da ipertrigliceridemia grave. La società vende i propri prodotti principalmente a grossisti e a fornitori di farmacie specializzate. Ha una collaborazione con Mochida Pharmaceutical Co., Ltd. per sviluppare e commercializzare prodotti farmaceutici e indicazioni basati sul principio attivo di Vascepa, l'acido omega-3, e sull'acido eicosapentaenoico. La società era precedentemente nota come Ethical Holdings plc e ha cambiato denominazione in Amarin Corporation plc nel 1999. Amarin Corporation plc è stata costituita nel 1989 e ha sede a Dublino, in Irlanda.
| Nome | Amarin Co. ADR |
| CEO | Aaron D. Berg |
| Sede centrale | Dublin,
du Irlanda |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 01/04/1993 |
| Dipendenti | 80 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | AMRN |
Frankfurt | EH3A.F |
Düsseldorf | EH3A.DU |
München | EH3A.MU |